Clinical Hold Placed on UCB/Immunomedics Lupus Biologic
This article was originally published in The Pink Sheet Daily
Executive Summary
Immunomedics says manufacturing issue should not derail Phase III trial.
You may also be interested in...
FDA Lifts Clinical Hold On UCB/Immunomedics Epratuzumab Lupus Trial
Firms will submit protocol amendments to institutional review boards.
FDA Lifts Clinical Hold On UCB/Immunomedics Epratuzumab Lupus Trial
Firms will submit protocol amendments to institutional review boards.
May The Schwarz Be With You: UCB Proposes $5.6 Bil. Acquisition
Existing Schwarz deal with Pfizer unaffected by merger that would create a neurology heavyweight.